Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States

By sjmartinez • November 15, 2022

Turbyfill C, Adams K, Tenforde MW, Murray NL, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW, Clark Files D, Hager DN, Shehu A, Prekker ME, Frosch AE, Exline MC, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Lauring AS, Khan A, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, June Gordon A, Qadir N, Chang SY, Mallow C, Rivas C, Kwon JH, Halasa N, Chappell JD, Grijalva CG, Rice TW, Stubblefield WB, Baughman A, Rhoads JP, Lindsell CJ, Hart KW, McMorrow M, Surie D, Self WH, Patel MM. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 Nov 15;40(48):6979-6986. doi: 10.1016/j.vaccine.2022.10.034. Epub 2022 Oct 24. PMID: 36374708.

Tags: case-control study, Control groups, covid-19, Publications, Pulmonary, Critical Care & Sleep Medicine, Research design, Test-negative, vaccine effectiveness

Merkel Cell Carcinoma Masquerading as Dermatitis

Freeman M, Gates G, Ahronowitz I. Merkel Cell Carcinoma Masquerading as Dermatitis. Cureus. 2026 Sep 19;18(9):e116561. doi: 10.7759/cureus.116561. PMID: 42903405; PMCID: PMC13680730.

Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath: JACC CardioOncology State-of-the-Art Review

Morad TT, Keykhaei M, Terraciano DA, Srivastava PK, Yang EH, Stein-Merlob AF. Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath: JACC CardioOncology[...]

Moving Beyond the Checklist: A Three-Tier Model for Integrating Geriatrics Expertise into the CMS Age-Friendly Era

Amir O, Sanon M. Moving Beyond the Checklist: A Three-Tier Model for Integrating Geriatrics Expertise into the CMS Age-Friendly Era. NEJM Catal Innov Care Deliv.[...]